Viatris Return on Tangible Equity 2010-2025 | VTRS
Current and historical return on tangible equity values for Viatris (VTRS) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Viatris Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2025-03-31 | $-3.79B | $-7.47B | 48.88% |
| 2024-12-31 | $-0.63B | $-7.57B | 7.84% |
| 2024-09-30 | $-0.88B | $-7.75B | 10.59% |
| 2024-06-30 | $-0.65B | $-8.23B | 7.12% |
| 2024-03-31 | $-0.06B | $-8.81B | 0.56% |
| 2023-12-31 | $0.05B | $-8.58B | -0.51% |
| 2023-09-30 | $1.83B | $-10.69B | -15.67% |
| 2023-06-30 | $1.85B | $-11.77B | -14.84% |
| 2023-03-31 | $1.90B | $-12.35B | -14.37% |
| 2022-12-31 | $2.08B | $-11.96B | -14.72% |
| 2022-09-30 | $0.80B | $-13.89B | -5.16% |
| 2022-06-30 | $0.76B | $-14.82B | -4.59% |
| 2022-03-31 | $0.17B | $-15.78B | -0.96% |
| 2021-12-31 | $-1.27B | $-17.76B | 6.92% |
| 2021-09-30 | $-1.92B | $-18.02B | 10.28% |
| 2021-06-30 | $-2.05B | $-18.65B | 12.61% |
| 2021-03-31 | $-1.73B | $-18.98B | 12.57% |
| 2020-12-31 | $-0.67B | $-19.08B | 5.94% |
| 2020-09-30 | $0.27B | $-8.24B | -3.01% |
| 2020-06-30 | $0.27B | $-8.73B | -2.93% |
| 2020-03-31 | $0.06B | $-9.11B | -0.65% |
| 2019-12-31 | $0.02B | $-9.36B | -0.17% |
| 2019-09-30 | $0.05B | $-9.75B | -0.45% |
| 2019-06-30 | $0.03B | $-10.52B | -0.31% |
| 2019-03-31 | $0.24B | $-10.67B | -2.11% |
| 2018-12-31 | $0.35B | $-11.25B | -2.99% |
| 2018-09-30 | $0.55B | $-11.97B | -4.54% |
| 2018-06-30 | $0.46B | $-11.83B | -3.80% |
| 2018-03-31 | $0.72B | $-12.19B | -5.91% |
| 2017-12-31 | $0.70B | $-12.14B | -5.75% |
| 2017-09-30 | $0.87B | $-11.96B | -7.12% |
| 2017-06-30 | $0.66B | $-12.17B | -5.26% |
| 2017-03-31 | $0.53B | $-12.11B | -5.15% |
| 2016-12-31 | $0.48B | $-12.56B | -6.04% |
| 2016-09-30 | $0.26B | $-13.42B | -4.66% |
| 2016-06-30 | $0.81B | $-3.22B | -29.80% |
| 2016-03-31 | $0.81B | $-2.57B | -32.00% |
| 2015-12-31 | $0.85B | $-2.84B | -32.98% |
| 2015-09-30 | $0.84B | $-2.20B | -31.87% |
| 2015-06-30 | $0.91B | $-2.47B | -31.20% |
| 2015-03-31 | $0.87B | $-2.79B | -27.42% |
| 2014-12-31 | $0.93B | $-3.12B | -27.47% |
| 2014-09-30 | $0.92B | $-3.32B | -25.72% |
| 2014-06-30 | $0.58B | $-3.46B | -17.71% |
| 2014-03-31 | $0.63B | $-3.63B | -21.04% |
| 2013-12-31 | $0.62B | $-3.90B | -22.54% |
| 2013-09-30 | $0.61B | $-2.12B | -25.36% |
| 2013-06-30 | $0.66B | $-2.39B | -27.03% |
| 2013-03-31 | $0.62B | $-2.67B | -24.48% |
| 2012-12-31 | $0.64B | $-2.38B | -26.03% |
| 2012-09-30 | $0.61B | $-2.30B | -24.05% |
| 2012-06-30 | $0.55B | $-2.76B | -21.93% |
| 2012-03-31 | $0.56B | $-2.41B | -23.22% |
| 2011-12-31 | $0.54B | $-2.64B | -22.54% |
| 2011-09-30 | $0.41B | $-2.29B | -17.54% |
| 2011-06-30 | $0.36B | $-2.32B | -14.97% |
| 2011-03-31 | $0.27B | $-2.25B | -11.07% |
| 2010-12-31 | $0.22B | $-2.49B | -9.14% |
| 2010-09-30 | $0.22B | $-2.59B | -9.11% |
| 2010-06-30 | $0.08B | $-2.28B | -3.05% |
| 2010-03-31 | $0.08B | $-2.40B | -3.20% |
| 2009-12-31 | $0.09B | $-2.57B | -3.50% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $10.610B | $14.739B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $145.009B | 27.20 |
| Elevance Health (ELV) | United States | $86.741B | 11.19 |
| CVS Health (CVS) | United States | $81.290B | 10.10 |
| Cencora (COR) | United States | $55.092B | 19.17 |
| DiDi Global (DIDIY) | China | $23.485B | 35.64 |
| Natera (NTRA) | United States | $22.560B | 0.00 |
| BioMerieux (BMXMF) | France | $16.856B | 0.00 |
| Solventum (SOLV) | United States | $13.071B | 13.84 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.026B | 0.00 |
| ICON (ICLR) | Ireland | $11.688B | 10.87 |
| Revvity (RVTY) | United States | $11.345B | 19.52 |
| CochLear (CHEOY) | Australia | $11.134B | 0.00 |
| Doximity (DOCS) | United States | $10.995B | 50.90 |
| Avantor (AVTR) | United States | $9.329B | 13.55 |
| HealthEquity (HQY) | United States | $9.272B | 40.61 |
| Medpace Holdings (MEDP) | United States | $8.792B | 23.35 |
| Sonic Healthcare (SKHHY) | Australia | $8.450B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.416B | 14.53 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.450B | 26.21 |
| BrightSpring Health Services (BTSG) | United States | $3.875B | 35.87 |
| Sotera Health (SHC) | United States | $3.491B | 19.84 |
| Surgery Partners (SGRY) | United States | $2.989B | 38.87 |
| Alignment Healthcare (ALHC) | United States | $2.898B | 0.00 |
| Concentras Parent (CON) | United States | $2.816B | 16.27 |
| Organon (OGN) | United States | $2.610B | 2.77 |
| GeneDx Holdings (WGS) | United States | $1.983B | 76.39 |
| Progyny (PGNY) | United States | $1.923B | 42.32 |
| Ardent Health Partners (ARDT) | United States | $1.920B | 8.18 |
| Premier (PINC) | United States | $1.884B | 14.30 |
| PACS (PACS) | United States | $1.629B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.622B | 32.43 |
| Teladoc Health (TDOC) | United States | $1.298B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.213B | 9.23 |
| Establishment Labs Holdings (ESTA) | $1.124B | 0.00 | |
| CareDx (CDNA) | United States | $1.105B | 17.26 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.011B | 0.00 |
| Agilon Health (AGL) | United States | $0.944B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.843B | 7.89 |
| QDM (QDMI) | Hong Kong, SAR China | $0.752B | 0.00 |
| Nutex Health (NUTX) | United States | $0.651B | 9.85 |
| Embecta (EMBC) | United States | $0.592B | 3.99 |
| LifeMD (LFMD) | United States | $0.553B | 0.00 |
| Enhabit (EHAB) | United States | $0.543B | 44.67 |
| InnovAge Holding (INNV) | United States | $0.514B | 0.00 |
| SBC Medicals (SBC) | United States | $0.495B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.474B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.470B | 10.58 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.445B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.258B | 0.00 |
| Oncology Institute (TOI) | United States | $0.237B | 0.00 |
| Beauty Health (SKIN) | United States | $0.202B | 0.00 |
| DocGo (DCGO) | United States | $0.156B | 25.50 |
| KindlyMD (KDLY) | United States | $0.150B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.104B | 0.00 |
| So-Young (SY) | China | $0.090B | 0.00 |
| OncoCyte (OCX) | United States | $0.079B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.075B | 0.00 |
| KindlyMD (NAKA) | United States | $0.070B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.060B | 0.00 |
| NeueHealth (NEUE) | United States | $0.060B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.057B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.056B | 0.00 |
| Biodesix (BDSX) | United States | $0.048B | 0.00 |
| ModivCare (MODV) | United States | $0.047B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.029B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.013B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.010B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.006B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |